Abstract
There is an obvious need to develop efficient countermeasure agents for use in emergency situations or as adjuncts to radiotherapy to protect healthy tissues from the consequences of an irradiation. To this end, we have investigated the capacity of norbadione A, a polyphenol extracted from the edible mushroom Bay boletus to reduce the toxicity of ionizing radiation towards cultured cells and whole-body exposed mice. Results indicate that this compound could slightly enhance the resistance of TK6 lymphoid cells to radiation and increase the survival rate in lethally irradiated mice. However, norbadione A was found to be cytotoxic at concentrations over 30 μM in vitro. The acute toxicity of this compound also precluded its use at higher doses for enhanced in vivo radioprotection. Norbadione A may nevertheless serve as lead for development of less toxic analogs with potentially cytoprotective/radioprotective activities.
Keywords: Norbadione A, Polyphenol, Radioprotective agent, Lymphocytes, radioprotective, polyphenol norbadione A, TK6, Fukushima's nuclear plant, conventional radiotherapy, sulfhydryl compounds, experimental radioprotective arsenal, reactive oxygen species (ROS), Resveratrol, Xerocomus badius
Letters in Drug Design & Discovery
Title: Evaluation of the Radioprotective Potential of the Polyphenol Norbadione A
Volume: 9 Issue: 1
Author(s): Antoine Le Roux, Elodie Josset, Sami Benzina, Brice Nadal, Marine Desage-El Murr, Benoit Heurtaux, Frederic Taran, Jean-Marc Denis, Thierry Le Gall, Stephane Meunier and Pierre Bischoff
Affiliation:
Keywords: Norbadione A, Polyphenol, Radioprotective agent, Lymphocytes, radioprotective, polyphenol norbadione A, TK6, Fukushima's nuclear plant, conventional radiotherapy, sulfhydryl compounds, experimental radioprotective arsenal, reactive oxygen species (ROS), Resveratrol, Xerocomus badius
Abstract: There is an obvious need to develop efficient countermeasure agents for use in emergency situations or as adjuncts to radiotherapy to protect healthy tissues from the consequences of an irradiation. To this end, we have investigated the capacity of norbadione A, a polyphenol extracted from the edible mushroom Bay boletus to reduce the toxicity of ionizing radiation towards cultured cells and whole-body exposed mice. Results indicate that this compound could slightly enhance the resistance of TK6 lymphoid cells to radiation and increase the survival rate in lethally irradiated mice. However, norbadione A was found to be cytotoxic at concentrations over 30 μM in vitro. The acute toxicity of this compound also precluded its use at higher doses for enhanced in vivo radioprotection. Norbadione A may nevertheless serve as lead for development of less toxic analogs with potentially cytoprotective/radioprotective activities.
Export Options
About this article
Cite this article as:
Le Roux Antoine, Josset Elodie, Benzina Sami, Nadal Brice, Desage-El Murr Marine, Heurtaux Benoit, Taran Frederic, Denis Jean-Marc, Le Gall Thierry, Meunier Stephane and Bischoff Pierre, Evaluation of the Radioprotective Potential of the Polyphenol Norbadione A, Letters in Drug Design & Discovery 2012; 9 (1) . https://dx.doi.org/10.2174/157018012798192900
DOI https://dx.doi.org/10.2174/157018012798192900 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Gene Strategies to Down-Regulate Gene Expression in Mammalian Cells
Current Pharmaceutical Design Gene Therapy of Cancer with Interleukin-12
Current Pharmaceutical Design Sirtuin Modulators: Targets for Metabolic Diseases and Beyond
Current Topics in Medicinal Chemistry Analogs of Cinnamic Acid Benzyl Amide As Nonclassical Inhibitors of Activated JAK2 Kinase
Current Cancer Drug Targets Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design Radiochemical Evaluation and <i>In Vitro</i> Assessment of the Targeting Ability of a Novel <sup>99m</sup>Tc-HYNIC-RGD for U87MG Human Brain Cancer Cells
Current Radiopharmaceuticals Editorial [Hot Topic: Overview of Antiangiogenic Therapies in Hematological Malignancies (Guest Editor: D. Ribatti)]
Current Cancer Drug Targets Blockade of Insulin-Like Growth Factor Type-1 Receptor with Cixutumumab (IMC-A12): A Novel Approach to Treatment for Multiple Cancers
Current Drug Targets The Herpesvirus Encoded dUTPase as a Potential Chemotherapeutic Target
Current Protein & Peptide Science DNA-drug Conjugates for Site-specific Delivery in Anti-cancer Therapy
Current Pharmacogenomics and Personalized Medicine 5-Nitro-Thiophene-Thiosemicarbazone Derivatives Present Antitumor Activity Mediated by Apoptosis and DNA Intercalation
Current Topics in Medicinal Chemistry Copper Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Subject Index To Volune 2
Current Cancer Therapy Reviews Recent Advances in Medicinal Chemistry of Sulfonamides. Rational Design as Anti-Tumoral, Anti-Bacterial and Anti-Inflammatory Agents
Mini-Reviews in Medicinal Chemistry Are Patient Self-Report Questionnaires as "Scientific" as Biomarkers in "Treat-totarget" and Prognosis in Rheumatoid Arthritis?
Current Pharmaceutical Design Xenobiotic Sulphation and its Variability During Inflammation: a Factor in Adverse Drug Reactions?
Current Drug Metabolism Connection between JAK/STAT and PPARγ Signaling During the Progression of Multiple Sclerosis: Insights into the Modulation of T-Cells and Immune Responses in the Brain
Current Molecular Pharmacology Study of Cancer Cell Lines with Fourier Transform Infrared (FTIR)/ Vibrational Absorption (VA) Spectroscopy
Current Physical Chemistry Melanoma and Epigenetic Treatment: Past and Future
Anti-Cancer Agents in Medicinal Chemistry Development and Validation of a Robust QSAR Model for Benzothiazole Hydrazone Derivatives as Bcl-XL Inhibitors
Letters in Drug Design & Discovery